BACKGROUND: Pediatric oncology patients are at increased risk for blood stream infections (BSI). Risk in the absence of severe neutropenia (absolute neutrophil count [ANC] ≥500/µl) is not well defined. PROCEDURE: In a retrospective cohort of febrile (temperature ≥38.0° for >1 hr or ≥38.3°) pediatric oncology patients with ANC ≥500/µl, a diagnostic prediction model for BSI was constructed using logistic regression modeling and the following candidate predictors: age, ANC, absolute monocyte count, body temperature, inpatient/outpatient presentation, sex, central venous catheter type, hypotension, chills, cancer diagnosis, stem cell transplant, upper respiratory symptoms, and exposure to cytarabine, anti-thymocyte globulin, or anti-GD2 antibody. The model was internally validated with bootstrapping methods. RESULTS: Among 932 febrile episodes in 463 patients, we identified 91 cases of BSI. Independently significant predictors for BSI were higher body temperature (Odds ratio [OR] 2.36 P < 0.001), tunneled external catheter (OR 13.79 P < 0.001), peripherally inserted central catheter (OR 3.95 P = 0.005), elevated ANC (OR 1.19 P = 0.024), chills (OR 2.09 P = 0.031), and hypotension (OR 3.08 P = 0.004). Acute lymphoblastic leukemia diagnosis (OR 0.34 P = 0.026), increased age (OR 0.70 P = 0.049), and drug exposure (OR 0.08 P < 0.001) were associated with decreased risk for BSI. The risk prediction model had a C-index of 0.898; after bootstrapping adjustment for optimism, corrected C-index 0.885. CONCLUSIONS: We developed a diagnostic prediction model for BSI in febrile pediatric oncology patients without severe neutropenia. External validation is warranted before use in clinical practice. Pediatr Blood Cancer 2015;62:262-268.
BACKGROUND: Pediatric oncology patients are at increased risk for blood stream infections (BSI). Risk in the absence of severe neutropenia (absolute neutrophil count [ANC] ≥500/µl) is not well defined. PROCEDURE: In a retrospective cohort of febrile (temperature ≥38.0° for >1 hr or ≥38.3°) pediatric oncology patients with ANC ≥500/µl, a diagnostic prediction model for BSI was constructed using logistic regression modeling and the following candidate predictors: age, ANC, absolute monocyte count, body temperature, inpatient/outpatient presentation, sex, central venous catheter type, hypotension, chills, cancer diagnosis, stem cell transplant, upper respiratory symptoms, and exposure to cytarabine, anti-thymocyte globulin, or anti-GD2 antibody. The model was internally validated with bootstrapping methods. RESULTS: Among 932 febrile episodes in 463 patients, we identified 91 cases of BSI. Independently significant predictors for BSI were higher body temperature (Odds ratio [OR] 2.36 P < 0.001), tunneled external catheter (OR 13.79 P < 0.001), peripherally inserted central catheter (OR 3.95 P = 0.005), elevated ANC (OR 1.19 P = 0.024), chills (OR 2.09 P = 0.031), and hypotension (OR 3.08 P = 0.004). Acute lymphoblastic leukemia diagnosis (OR 0.34 P = 0.026), increased age (OR 0.70 P = 0.049), and drug exposure (OR 0.08 P < 0.001) were associated with decreased risk for BSI. The risk prediction model had a C-index of 0.898; after bootstrapping adjustment for optimism, corrected C-index 0.885. CONCLUSIONS: We developed a diagnostic prediction model for BSI in febrile pediatric oncology patients without severe neutropenia. External validation is warranted before use in clinical practice. Pediatr Blood Cancer 2015;62:262-268.
Authors: Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young Journal: Clin Infect Dis Date: 2002-02-13 Impact factor: 9.079
Authors: Hana Hakim; Patricia M Flynn; Deo Kumar Srivastava; Katherine M Knapp; Chenghong Li; James Okuma; Aditya H Gaur Journal: Pediatr Infect Dis J Date: 2010-01 Impact factor: 2.129
Authors: Philipp Agyeman; Christoph Aebi; Andreas Hirt; Felix K Niggli; David Nadal; Arne Simon; Hulya Ozsahin; Udo Kontny; Thomas Kühne; Maja Beck Popovic; Kurt Leibundgut; Nicole Bodmer; Roland A Ammann Journal: Pediatr Infect Dis J Date: 2011-07 Impact factor: 2.129
Authors: M E Santolaya; A M Alvarez; C L Avilés; A Becker; J Cofré; N Enríquez; M O'Ryan; E Payá; C Salgado; P Silva; J Tordecilla; M Varas; M Villarroel; T Viviani; M Zubieta Journal: Clin Infect Dis Date: 2002-08-23 Impact factor: 9.079
Authors: R Dommett; J Geary; S Freeman; J Hartley; M Sharland; A Davidson; R Tulloh; M Taj; S Stoneham; J C Chisholm Journal: Eur J Cancer Date: 2009-07-16 Impact factor: 9.162
Authors: Kaitlin Shinn; Martha Wetzel; Nicholas P DeGroote; Frank Keller; Michael Briones; James Felker; Sharon Castellino; Tamara P Miller Journal: Pediatr Blood Cancer Date: 2020-09-02 Impact factor: 3.167
Authors: Adam J Esbenshade; Zhiguo Zhao; Catherine Aftandilian; Raya Saab; Rachel L Wattier; Melissa Beauchemin; Tamara P Miller; Jennifer J Wilkes; Michael J Kelly; Alison Fernbach; Michael Jeng; Cindy L Schwartz; Christopher C Dvorak; Yu Shyr; Karl G M Moons; Maria-Luisa Sulis; Debra L Friedman Journal: Cancer Date: 2017-05-23 Impact factor: 6.860
Authors: Gabrielle M Haeusler; Karin A Thursky; Monica A Slavin; Franz E Babl; Richard De Abreu Lourenco; Zoe Allaway; Francoise Mechinaud; Robert Phillips Journal: EClinicalMedicine Date: 2020-01-07
Authors: Stefan Schöning; Anke Barnbrock; Konrad Bochennek; Kathrin Gordon; Andreas H Groll; Thomas Lehrnbecher Journal: Antibiotics (Basel) Date: 2022-07-05